Maximum Dose of Bilastine for Chronic Urticaria
The maximum recommended dose of bilastine for adults with chronic urticaria is 80 mg once daily (4 times the standard 20 mg dose).
Dosing Algorithm
First-Line Treatment
- Start with standard dose: Bilastine 20 mg once daily 1
- Assess response after 2-4 weeks using the Urticaria Control Test (UCT)
Up-Dosing Strategy
If inadequate control is achieved (UCT score <16):
- Increase to 40 mg once daily (2x standard dose)
- If still inadequate after 2 weeks, increase to 80 mg once daily (4x standard dose) 1
This 4-fold up-dosing to 80 mg daily represents the maximum recommended dose and is explicitly endorsed by international urticaria guidelines as an acceptable second-line treatment option 2.
Evidence Supporting Maximum Dose
The 80 mg dose has been extensively validated:
- In cold contact urticaria, 80 mg bilastine achieved a 95% response rate with 60% of patients becoming symptom-free 3
- This dose significantly reduced inflammatory mediators (histamine, IL-6, IL-8) compared to standard dosing 3
- A 2023 systematic review confirmed bilastine can be safely up-dosed to 4 times the conventional dose with Grade A recommendation 4
- Recent 2024-2025 studies continue to demonstrate efficacy and safety at 40 mg twice daily (equivalent to 80 mg total daily dose) 5
Safety Profile at Maximum Dose
Critical advantage: Bilastine maintains excellent tolerability even at 4-fold dosing:
- No dose-dependent increase in sedation due to P-glycoprotein substrate properties preventing blood-brain barrier penetration 6, 4
- No cardiotoxicity reported at supratherapeutic doses 2, 4
- Well-tolerated without systemic complications 4
- Adverse events at 80 mg remain comparable to standard 20 mg dosing 3
Important Clinical Considerations
When to Up-Dose
- Only after confirming inadequate control with standard dosing for 2-4 weeks 1
- Use UCT score <16 as the threshold for inadequate control 1
Duration Before Switching
- Allow adequate trial at each dose level (minimum 2 weeks) before escalating
- Approximately 14.7% of patients may not respond even at maximum dose and will require alternative therapy (omalizumab or cyclosporine) 7
Step-Down Protocol
Once complete control is achieved (UCT ≥16 for 3 consecutive months):
- Reduce by no more than 1 tablet (20 mg) per month 1
- If breakthrough symptoms occur, return to the last effective dose
Common Pitfall to Avoid
Do not combine bilastine with another antihistamine instead of up-dosing. Guidelines explicitly recommend up-dosing a single second-generation antihistamine up to 4-fold rather than adding a second antihistamine, as combination therapy lacks evidence of synergistic benefit 1, 5.